Non-Small Cell Cancer

The FDA granted fast track designation to bemcentinib in combination with an anti-PD-L1 agent for treatment of patients with AXL-positive advanced or metastatic non-small cell lung cancer.

Patritumab deruxtecan induced a 39% overall response rate among patients with advanced, EGFR-mutant non-small cell lung cancer, according to phase 1 study results presented during the virtual ASCO Annual Meeting.

The FDA approved amivantamab-vmjw for treatment of adults with non-small cell lung cancer who harbor EGFR exon 20 insertion mutations.

The addition of first-line ipilimumab to pembrolizumab did not improve outcomes for patients with metastatic non-small cell lung cancer who had PD-L1 tumor proportion scores of 50% or greater and no targetable EGFR or ALK aberrations.